Valneva (NASDAQ:VALN) Cut to “Sell” at The Goldman Sachs Group

Valneva (NASDAQ:VALN) was downgraded by equities researchers at The Goldman Sachs Group from a “neutral” rating to a “sell” rating in a report issued on Wednesday, Marketbeat reports. They presently have a $4.90 target price on the stock. The Goldman Sachs Group’s price target points to a potential downside of 17.37% from the stock’s current price.

Separately, Guggenheim set a $11.00 target price on Valneva in a research report on Thursday, April 16th. Three equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Valneva presently has a consensus rating of “Hold” and an average price target of $11.98.

Valneva Trading Down 1.8%

Valneva stock opened at $5.93 on Wednesday. The stock has a market cap of $510.63 million, a P/E ratio of -3.75 and a beta of 1.97. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.38 and a quick ratio of 1.85. Valneva has a 1 year low of $5.43 and a 1 year high of $12.25. The firm’s 50 day moving average price is $8.74 and its 200-day moving average price is $9.11.

Valneva (NASDAQ:VALN) last released its quarterly earnings data on Sunday, February 15th. The company reported ($0.68) earnings per share (EPS) for the quarter. The company had revenue of $55.92 million for the quarter. Valneva had a negative net margin of 67.64% and a negative return on equity of 76.81%. On average, equities analysts predict that Valneva will post -0.81 earnings per share for the current fiscal year.

Institutional Trading of Valneva

A number of large investors have recently made changes to their positions in the business. Marex Group plc purchased a new stake in Valneva during the 2nd quarter valued at $64,000. JPMorgan Chase & Co. purchased a new stake in Valneva during the 3rd quarter valued at $124,000. VSM Wealth Advisory LLC raised its holdings in Valneva by 125.0% during the 3rd quarter. VSM Wealth Advisory LLC now owns 9,000 shares of the company’s stock valued at $110,000 after buying an additional 5,000 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in Valneva during the 4th quarter valued at $44,000. Finally, XTX Topco Ltd purchased a new stake in Valneva during the 4th quarter valued at $94,000. 11.39% of the stock is currently owned by institutional investors.

Valneva Company Profile

Valneva SE is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases. Headquartered in Saint-Herblain, France, the company applies inactivated whole-cell and recombinant technology platforms to address public health needs. Valneva’s research and development efforts span a range of viral and bacterial pathogens, with an emphasis on travel-related and emerging infectious diseases.

Among its marketed products, Valneva offers IXIARO®/JESPECT® for the prevention of Japanese encephalitis and DUKORAL® for the prevention of cholera and diarrhea caused by enterotoxigenic Escherichia coli.